Summary
Merck & Co., Inc. reported sales of $14.49 billion for the first quarter of 2023, a decrease of 9% year-over-year, or 5% excluding foreign exchange impacts. This decline was primarily driven by significantly lower sales of Lagevrio (COVID-19 antiviral), which generated $392 million compared to $3.2 billion in the prior year period. Other contributing factors to the sales decrease included lower sales in the diabetes franchise (Januvia/Janumet) and the pneumococcal vaccine (Pneumovax 23). Despite the revenue decline, the company's R&D expenses increased significantly by 66% to $4.3 billion, largely due to the $1.2 billion charge for the acquisition of Imago BioSciences and upfront payments for collaborations. The company also announced a significant agreement to acquire Prometheus Biosciences for approximately $10.8 billion, expected to close in the third quarter of 2023. This strategic move aims to bolster its pipeline in immune-mediated diseases. Net income attributable to Merck & Co., Inc. decreased to $2.82 billion, or $1.11 per share, from $4.31 billion, or $1.70 per share, in the first quarter of 2022. This decrease reflects the lower sales and increased R&D expenses, partially offset by a significant improvement in gross margin due to lower Lagevrio sales and lower amortization expenses. The company's strategic acquisitions and R&D investments signal a focus on future growth areas, though current financial results are impacted by the wind-down of certain pandemic-related products.
Financial Highlights
53 data points| Revenue | $14.49B |
| Cost of Revenue | $3.93B |
| Gross Profit | $10.56B |
| R&D Expenses | $4.28B |
| SG&A Expenses | $2.48B |
| Interest Expense | $242.00M |
| Net Income | $2.82B |
| EPS (Basic) | $1.11 |
| EPS (Diluted) | $1.11 |
| Shares Outstanding (Basic) | 2.54B |
| Shares Outstanding (Diluted) | 2.55B |
Key Highlights
- 1Total sales decreased by 9% to $14.49 billion, primarily due to a significant drop in Lagevrio sales ($392M vs $3.2B YoY).
- 2Research and Development (R&D) expenses surged by 66% to $4.3 billion, heavily influenced by the $1.2 billion acquisition cost of Imago BioSciences and other collaboration upfront payments.
- 3The company announced a definitive agreement to acquire Prometheus Biosciences for approximately $10.8 billion, signaling a strategic expansion into immune-mediated diseases.
- 4Net income attributable to Merck & Co., Inc. fell to $2.82 billion ($1.11 EPS) from $4.31 billion ($1.70 EPS) in the prior year quarter.
- 5Gross margin improved significantly to 72.9% from 66.2% due to lower sales of low-margin Lagevrio and reduced amortization expenses.
- 6Keytruda demonstrated strong growth, with sales up 20% to $5.8 billion, driven by new indications and increased demand across various cancer types.
- 7The company settled Zetia antitrust litigation for $572.5 million, recorded in the first quarter of 2023.